A phase 2, randomized, parallel group, multicenter, multinational study for the evaluation of safety of four fixed dose regimens of DU 176b in subjects with non-valvular atrial fibrillation

Trial Profile

A phase 2, randomized, parallel group, multicenter, multinational study for the evaluation of safety of four fixed dose regimens of DU 176b in subjects with non-valvular atrial fibrillation

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Edoxaban (Primary) ; Warfarin
  • Indications Stroke; Thromboembolism; Thrombosis
  • Focus Adverse reactions; Biomarker; Pharmacokinetics; Therapeutic Use
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Nov 2012 Planned number of patients changed from 1146 to 2000 as reported by European Clinical Trials Database.
    • 18 Aug 2009 Results reported at 22nd Congress of the International Society on Thrombosis and Haemostasis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top